Logo
x

Search

Subscribe Now

SetPoint Medical

SetPoint Medical Reports the US FDA’s IDE Approval to Initiate Neuroimmune Modulation Platform’s Evaluation for Relapsing-Remitting Multiple Sclerosis

SetPoint Medical Reports the US FDA’s IDE Approval to Initiate Neuroimmune Modulation Platform’s Evaluation for Relapsing-Remittin...

  • October 3, 2024
SetPoint Medical’s Neuroimmune Modulation Platform Obtains the US FDA’s Breakthrough Device Designation to Treat Multiple Sclerosis

SetPoint Medical’s Neuroimmune Modulation Platform Obtains the US FDA’s Breakthrough Device Designation to Treat Multiple Sclerosi...

  • March 14, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.